AXIS Capital Holdings Limited logo AXS - AXIS Capital Holdings Limited

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 15
HOLD 14
SELL 0
STRONG
SELL
0
| PRICE TARGET: $116.80 DETAILS
HIGH: $126.00
LOW: $108.00
MEDIAN: $116.00
CONSENSUS: $116.80
UPSIDE: 17.23%

Stock News

AXIS Celebrates 25th Anniversary, Launches Global Brand Campaign Spotlighting Its Focus on Specialty Underwriting Leadership

AXIS Celebrates 25th Anniversary, Launches Global Brand Campaign Spotlighting Its Focus on Specialty Underwriting Leadership

PEMBROKE, Bermuda, Sept. 08, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited (“AXIS” or the “Company”) (NYSE: AXS) today unveiled a new brand campaign celebrating its 25-year history of providing specialty insurance and reinsurance solutions to customers. The company was formed in the aftermath of the September 11 tragedy to address a void in the market for specialist capacity. Since its modest beginnings as a start-up, AXIS has grown into a global specialty leader with $35 billion in total assets and $7.7 billion in total capital as of year-end 2025.

Sep 08, 2026 05:00 AM • globenewswire.com
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. SUMMIT (Studying NMDA and Sigma-1 in Smoking Cessation Treatment) is a Phase 3 randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 as a smoking cessation treatment in adults.

Aug 31, 2026 03:00 AM • globenewswire.com
AXS PFD E Offers Competitive Yield Versus Other Insurance Companies

AXS PFD E Offers Competitive Yield Versus Other Insurance Companies

AXIS Capital Holdings Limited offers diversified specialty insurance and reinsurance, with strong A+ credit ratings and a BBB-rated preferred stock AXS.PR.E. AXS reported 15% YOY growth in both premiums written and diluted book value, with a solid 93.1% combined ratio, though reinsurance premiums declined 25%. The fixed-rate, non-cumulative Series E preferred AXS.PR.E offers QDI-eligible dividends and BBB credit quality, appealing for income-focused investors seeking stability.

Aug 14, 2026 04:00 AM • seekingalpha.com

Price Targets